Clinical trials
Leukemia, Myelomonocytic, Chronic trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 5 |
| Completed | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Novartis Pharmaceuticals | 2 |
| Biocity Biopharmaceutics Co., Ltd. | 1 |
| Bristol-Myers Squibb | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| Hutchison Medipharma Limited | 1 |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 1 |
| Peking University People's Hospital | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Takeda | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelomonocytic, Chronic | 13 |
| Myelodysplastic Syndromes | 8 |
| Leukemia, Myeloid, Acute | 7 |
| Anemia, Refractory, with Excess of Blasts | 1 |
| Leukemia, Myeloid | 1 |
| Neoplasms | 1 |
| Sarcoma, Myeloid | 1 |
Trials
Showing 51 to 13 of 13. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.